Physician profile
Nasir Gebi
NPI 1861968612
$1,975.96
in general payments reported to CMS, 2019-2025
11 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $261 · 2023: $441 · 2024: $185 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965 · Honoraria: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.03 |
| Honoraria | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alpha Cognition USA, INC. | $750.00 | 2025 | Zunveyl |
| Acadia Pharmaceuticals INC | $493.62 | 2022-2025 | Nuplazid |
| Ucb, INC. | $250.93 | 2023-2024 | Nayzilam, Briviact |
| Otsuka America Pharmaceutical, INC. | $136.63 | 2023-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $120.83 | 2025 | Fanapt |
| Urovant Sciences INC | $113.32 | 2022 | |
| Neurocrine Biosciences, INC. | $26.42 | 2025 | |
| Sunovion Pharmaceuticals INC. | $25.53 | 2022 | |
| Protega Pharmaceutials INC | $23.65 | 2025 | Roxybond |
| Teva Pharmaceuticals USA, INC. | $20.07 | 2023 | Austedo Xr |
| Sumitomo Pharma America, INC. | $14.96 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasir Gebi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.